Brazilian Registry of Bone Biopsy (REBRABO) : design, data elements and methodology

• Autor(a) principal: Oliveira, Rodrigo Bueno de (Médico)
• Data de Publicação: 2014
• Outros Autores: Barreto, Fellype de Carvalho, Custódio, Melani Ribeiro, Gueiros, José Edevanilson Barros, Neves, Carolina Lara, Karohl, Cristina, Sampaio, Elisa de Albuquerque, Costa, Rackel Mota da, Canziani, Maria Eugênia, Moysés, Rosa Maria Affonso, Carvalho, Aluízio Barbosa
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/185153
• topic: Doenças ósseas; Insuficiência renal crônica; Registros eletrônicos de saúde; Bone diseases; Electronic health records; Renal insufficiency; Chronic

Mineral bone disorder (MBD) is a common condition in chronic kidney disease (CKD) patients and causes significant morbidity and mortality. Data involving prevalence of alterations in bone histological patterns, impact of different treatments and its repercussion in outcomes, such as bone fractures, hospitalization, cardiovascular disease and mortality, are scarce. Data bank registry can be a valuable tool to understand epidemiological aspects of MBD CKD. The Brazilian Registry of Bone Biopsy (REBRABO) will be a national registry, coordinating by the Brazilian Society of Nephrology - Committee of MBD-CKD. Objective: To describe REBRABO´s design, elements of data and methodology. Methods: Will be an online national observational and multicentric data registry divided in two phases (retrospective, 1st phase) and prospective (2nd phase), including information from bone tissue histomorphometric analysis and demographics, clinical and laboratorial data from CKD-MBD patients. Results: The REBRABO´s first phase will explore data on demographics, clinical, laboratorial and bone histomorphometric analysis data from January/1986 to December/2013. The first results are expected in early 2015. Conclusion: Studies in the field of CKD-MBD are needed, particularly those analyzing its prevalence, associations between demographic, clinical, histological parameters, and major outcomes. The REBRABO will be a unique retrospective and prospective research platform including bone biopsy data in CKD-MBD patients.